Von Hippel Lindau blocking peptide

Cat No. GTX89268-PEP

Species	Human
Package	100 μg ($239)

Datasheet

APPLICATION

Product Note

The peptide was used in the production of GTX89268.

PROPERTIES

Form

Lyophilized powder

Buffer

Lyophilized from 5% (v/v) acetonitrile/H₂O. Reconstitute pellet in 200μl distilled water to obtain a 0.5mg/ml peptide solution.

Storage

Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.

Region/Sequence

C-RSLVKPENYRRLD

Note

For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.

TARGET

Synonyms

Von Hippel-Lindau Tumor Suppressor , Hrca1 , Rca1 , Vhl1 , Pvhl , Vhl

Background

Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of this gene is the basis of familial inheritance of VHL syndrome. The protein encoded by this gene is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. Alternatively spliced transcript variants encoding distinct isoforms have been observed. [provided by RefSeq, Jul 2008]

Research Area

- Cancer
- Cancer
- Hypoxia

REFERENCE

There are currently no references for Von Hippel Lindau blocking peptide (GTX89268-PEP). Be the first to share your publications with this product.

Submit a Reference